Trial Profile
COVID-19: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Clinical Study Evaluating the Safety and Immunogenicity of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adult Health Care Workers in Mainz (Germany)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Zorecimeran (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors CureVac
- 20 Jun 2022 Status changed from active, no longer recruiting to completed.
- 20 Jul 2021 Planned End Date changed from 30 Apr 2022 to 12 Jul 2022.
- 20 Jul 2021 Planned primary completion date changed from 30 Jun 2021 to 30 Jun 2022.